Autoimmune Encephalitides: A Broadening Field of Treatable Conditions
Neurologist 22:1-13, Kalman, B., 2017
Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016
Evidence-based Guideline: Clinical Evaluation and Treatment of Transverse Myelitis
Neurol 77:2128-2134, Scott, T.F.,et al, 2011
Natalizumab and Progressive Multifocal Leukoencephalopathy: What are the Causal Factors and Can It be Avoided?
Arch Neurol 67:923-930, Warnke,C., et al, 2010
Best Practice Recommendations for the Selection and Management of Patients with Multiple Sclerosis Receiving Natalizumab Therapy
Mutliple Sclerosis 15:S26-S36, Coyle,P.K.,et al, 2009
Natalizumab for Multiple Sclerosis
NEJM 356:2622-2629, Ransohoff,R.M., 2007
Natalizumab (Tysabri) Treatment for Relapsing Multiple Sclerosis
The Neurologist 13:182-187, Johnson,K.P., 2007
Guidelines on the Detection of Paraneoplastic Anti-Neuronal-Specific Antibodies
Neurol 45:1937-1941, Moll,J.W.B.,et al, 1995
2024 Guide for the Primary Prevention of Stroke:A Guideline From the American Heart Association/American Stroke Association
Stroke 55:e344-e424, Bushnell,C.,et al, 2024
Clinicopathologic Conference, Seizure from Neurocysticercosis
NEJM 385:1894-1902, Case 34-2021, 2021
Migraine
NEJM 377:553-561, Charles, A., 2017
Recommendations for the Management of Cerebral and Cerebellar Infarction with Swelling
Stroke 45:1222-1238, Wijdicks, E.F.M.,et al, 2014
Evidence-based Guideline Update: NSAIDs and Other Complementary Treatments for Episodic Migraine Prevention in Adults
Neurol 78:1346-1353, Holland,S.,et al, 2012
Hyperosmolar Therapy for Raised Intracranial Pressure
NEJM 367:746-752, Ropper, A.H., 2012
Diagnosis and Management of Cerebral Venous Thrombosis: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association
Stroke 42:1158-1192, Saposnik,G.,et al, 2011
Predictors of Neurologic Outcome in Hypothermia After Cardiac Arrest
Ann Neurol 68:907-914, Fugate,J.E.,et al, 2010
The Management of Encephalitis: Clinical Practice Guidelines by the Infectious Disease Society of America
Clinical Infectious Diseases 47:303-327, Tunkel, A.R.,et al, 2008
Neutralizing Antibodies to Interferon Beta: Assessment of Their Clinical and Radiographic Impact: An Evidence Report
Neurol 68:977-984, Goodin,D.S.,et al, 2007
Assessment of Declofenac or Spinal Manipulative Therapy, Or Both, in Addition to Recommended First-Line Treatment for Acute Low Back Pain: A Randomised Controlled Trial
Lancet 370:1638-1643, Hancock,M.J., et al, 2007
Chronic Daily Headache
NEJM 354:158-165, Dodick,D.W., 2006
Neutralizing Anti-IFN-B Antibodies
Neurol 65:6-8, Giovannoni,G.&Goodman,A., 2005
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Recommended Diagnostic Criteria for Paraneoplastic Neurological Syndromes
JNNP 75:1135-1140,1090, Graus,F.,et al, 2004
Traumatic Brain Injury
Lancet 356:923-929, Ghajar,J., 2000
Anticytokine Antibodies in Beta Interferon-Trated MS Patients and the Need for Testing
Neurol 49:647-650, Pachner,A.R., 1997
Laboratory Evaluation in the Diagnosis of Lyme Disease
Ann Int Med 127:1109-1123, 1106-11081997., Tugwell,P.,et al, 1997
Results of a Computerized Screening of Stroke Patients for Unjustified Hospital Stay
Stroke 27:639-644, Goldman,R.S.,et al, 1996
Practice Parameters for the Diagnosis of Patients with Nervous System Lyme Borreliosis (Lyme Disease)
Neurol 46:619-627, 8811996., Halperin,J.J.,et al, 1996
Guidelines for Physicians with Patients on IFNB-1b:The Use of an Assay for Neutralizing Antibodies (NAB)
Neurol 47:865-866, Paty,D.,et al, 1996
Concussion in Sports, Guidelines for the Prevention of Catastrophic Outcome
JAMA 266:2867-2869, Kelly,J.P.,et al, 1991